PureTech Health - PRTC Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 252.50
▼ -7.5 (-2.88%)

This chart shows the closing price for PRTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PureTech Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTC

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for PureTech Health in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 252.50.

This chart shows the closing price for PRTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in PureTech Health. This rating has held steady since November 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/7/2021Liberum CapitalBoost TargetBuyGBX 560 ➝ GBX 580
11/26/2021Liberum CapitalReiterated RatingBuy
11/3/2021Liberum CapitalBoost TargetBuyGBX 540 ➝ GBX 560
8/24/2021Liberum CapitalReiterated RatingBuyGBX 540
5/27/2021Peel HuntReiterated RatingBuyGBX 930
5/27/2021Peel HuntReiterated RatingBuyGBX 930
4/15/2021Liberum CapitalReiterated RatingBuyGBX 550
1/19/2021Jefferies Financial GroupReiterated RatingBuyGBX 475
1/18/2021Liberum CapitalReiterated RatingBuyGBX 490
7/29/2020Liberum CapitalBoost TargetBuyGBX 450 ➝ GBX 490
7/8/2020Peel HuntReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/23/2020Liberum CapitalReiterated RatingBuy
6/23/2020Peel HuntReiterated RatingBuy
6/16/2020Peel HuntReiterated RatingBuy
6/16/2020Liberum CapitalReiterated RatingBuy
6/9/2020Liberum CapitalReiterated RatingBuy
6/8/2020Peel HuntReiterated RatingBuy
6/2/2020Peel HuntReiterated RatingBuyGBX 480
6/2/2020Peel HuntReiterated RatingBuyGBX 480
5/28/2020Liberum CapitalReiterated RatingBuyGBX 450
5/26/2020Peel HuntReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/23/2020Liberum CapitalReiterated RatingBuy
4/23/2020Peel HuntReiterated RatingBuy
4/14/2020Liberum CapitalReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/18/2020Liberum CapitalReiterated RatingBuy
3/3/2020Peel HuntReiterated RatingBuy
2/25/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/23/2020Peel HuntReiterated RatingBuyGBX 480
1/23/2020Liberum CapitalReiterated RatingBuyGBX 420 ➝ GBX 450
1/23/2020Peel HuntReiterated RatingBuyGBX 480
1/16/2020Peel HuntReiterated RatingBuy
1/13/2020Liberum CapitalLower TargetBuyGBX 450 ➝ GBX 420
1/10/2020Peel HuntReiterated RatingBuy
12/19/2019Peel HuntReiterated RatingBuyGBX 480
12/13/2019Peel HuntReiterated RatingBuy
12/9/2019Liberum CapitalReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/22/2019Peel HuntBoost TargetBuyGBX 380 ➝ GBX 460
11/18/2019Peel HuntReiterated RatingBuyGBX 380 ➝ GBX 460
11/15/2019Liberum CapitalReiterated RatingBuyGBX 347 ➝ GBX 300
11/4/2019Peel HuntReiterated RatingBuy
10/2/2019Peel HuntReiterated RatingBuyGBX 380
10/2/2019Peel HuntReiterated RatingBuyGBX 380
9/23/2019Peel HuntReiterated RatingBuy
9/9/2019Peel HuntReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
8/27/2019Liberum CapitalBoost TargetBuyGBX 336 ➝ GBX 347
8/27/2019Peel HuntReiterated RatingBuy
8/1/2019Peel HuntReiterated RatingBuy
7/17/2019Liberum CapitalReiterated RatingBuy
7/17/2019Peel HuntReiterated RatingBuyGBX 344 ➝ GBX 380
7/11/2019Peel HuntReiterated RatingBuy
7/11/2019Liberum CapitalReiterated RatingBuy
7/5/2019Jefferies Financial GroupBoost TargetBuyGBX 280 ➝ GBX 340
7/3/2019Peel HuntReiterated RatingBuyGBX 344
7/2/2019Liberum CapitalBoost TargetBuyGBX 308 ➝ GBX 336
6/28/2019Peel HuntReiterated RatingBuyGBX 344
6/13/2019Liberum CapitalReiterated RatingBuy
6/13/2019Peel HuntReiterated RatingBuy
6/3/2019Liberum CapitalReiterated RatingBuy
6/3/2019Peel HuntReiterated RatingBuy
5/16/2019Liberum CapitalReiterated RatingBuy
5/13/2019Peel HuntReiterated RatingBuy
5/2/2019Peel HuntReiterated RatingBuy
4/24/2019Liberum CapitalReiterated RatingBuy
4/24/2019Peel HuntReiterated RatingBuy
4/17/2019Jefferies Financial GroupReiterated RatingBuyGBX 255
4/17/2019Peel HuntReiterated RatingBuy
4/15/2019Liberum CapitalReiterated RatingBuy
4/11/2019Peel HuntReiterated RatingBuyGBX 320 ➝ GBX 344
4/2/2019Peel HuntReiterated RatingBuy
3/18/2019Peel HuntReiterated RatingBuy
3/18/2019Liberum CapitalReiterated RatingBuy
3/7/2019Jefferies Financial GroupReiterated RatingBuyGBX 255
3/7/2019Peel HuntReiterated RatingBuyGBX 313 ➝ GBX 320
3/7/2019Liberum CapitalReiterated RatingBuy
2/14/2019Liberum CapitalReiterated RatingBuy
2/14/2019Peel HuntReiterated RatingBuy
1/31/2019Peel HuntReiterated RatingBuy
1/24/2019Peel HuntReiterated RatingBuy
1/7/2019Peel HuntReiterated RatingBuy
1/4/2019Jefferies Financial GroupBoost TargetBuyGBX 245 ➝ GBX 255
12/24/2018Peel HuntReiterated RatingBuy
12/18/2018Peel HuntReiterated RatingBuy
12/10/2018Liberum CapitalReiterated RatingBuy
12/6/2018Peel HuntReiterated RatingBuyGBX 313
11/27/2018Liberum CapitalReiterated RatingBuy
11/26/2018Peel HuntReiterated RatingBuy
11/1/2018Peel HuntReiterated RatingBuy
10/26/2018Liberum CapitalReiterated RatingBuy
10/3/2018Peel HuntReiterated RatingBuy
9/11/2018Jefferies Financial GroupBoost TargetBuyGBX 245 ➝ GBX 255
9/11/2018Peel HuntReiterated RatingBuy
9/11/2018Liberum CapitalReiterated RatingBuy
9/4/2018Peel HuntReiterated RatingBuy
8/9/2018Peel HuntReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingBuy
7/26/2018Liberum CapitalReiterated RatingBuy
7/20/2018Peel HuntReiterated RatingBuy
7/20/2018Liberum CapitalReiterated RatingBuy
7/12/2018Peel HuntReiterated RatingBuy
7/3/2018Peel HuntReiterated RatingBuy
6/19/2018Peel HuntReiterated RatingBuy
5/31/2018Peel HuntReiterated RatingBuy
5/9/2018Jefferies Financial GroupReiterated RatingBuyGBX 245
5/9/2018Peel HuntReiterated RatingBuyGBX 313
4/16/2018Liberum CapitalReiterated RatingBuyGBX 248
4/4/2018Peel HuntReiterated RatingBuy
3/13/2018Liberum CapitalReiterated RatingBuyGBX 248
3/2/2018N+1 SingerReiterated RatingBuy
3/1/2018Peel HuntReiterated RatingBuyGBX 313
3/1/2018Liberum CapitalReiterated RatingBuyGBX 248
2/20/2018Peel HuntReiterated RatingBuyGBX 313
2/20/2018Numis SecuritiesReiterated RatingBuyGBX 259
2/1/2018Peel HuntReiterated RatingBuyGBX 313
1/29/2018Numis SecuritiesReiterated RatingBuyGBX 259
(Data available from 1/29/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/30/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
PureTech Health logo
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: GBX 252.50
Low: 248
High: 257

50 Day Range

MA: GBX 270.78
Low: 252.50
High: 294.50

52 Week Range

Now: GBX 252.50
Low: 145.80
High: 300

Volume

217,235 shs

Average Volume

200,012 shs

Market Capitalization

£703.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of PureTech Health?

The following Wall Street sell-side analysts have issued research reports on PureTech Health in the last year:
View the latest analyst ratings for PRTC.

What is the current price target for PureTech Health?

0 Wall Street analysts have set twelve-month price targets for PureTech Health in the last year. has the lowest price target set, forecasting a price of £100,000 for PureTech Health in the next year.
View the latest price targets for PRTC.

What is the current consensus analyst rating for PureTech Health?

PureTech Health currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PRTC.

What other companies compete with PureTech Health?

How do I contact PureTech Health's investor relations team?

PureTech Health's physical mailing address is 501 Boylston St Ste 6102, BOSTON, MA 02116-3769, United States. The company's listed phone number is +1-617-4822333. The official website for PureTech Health is puretechhealth.com. Learn More about contacing PureTech Health investor relations.